Gooses quote:
" Posted On: 05/29/2021 11:22:56 AM
Posted
Gooses quote:
" Posted On: 05/29/2021 11:22:56 AM
Posted By: Goosebumps
Re: gestalt2 #92238
Quote:
The longhaulers data will be compelling but will be only P2 data so it will be only able to form a future P3 trial. There could be a lack of public interest in the p2 data
Not saying it will happen. But there is a remote chance a phase 2 can be approved. Especially if it shows great efficacy. You would think the best path for that would be a BTD since there is no current drug treatment approved for LH’s. Let me state that again... remote chance it could happen. But there is that chance... just sayin..."
Me:
Not to be a pessimist Goose but with the US fda? Not a chance for them to be so forward thinking as CYDY is not a member of the US big pharma club as we know it is. Sorry, just had to make that point as they (fda), have not even offered any help of any kind with a world wide emergency pandemic continuing, as in, Philippines, India, Brazil, South America and even in Japan like they should be. THERE IS NO PROFIT for the big pharmas when CYDY gets an approval some where in the Milky way Galaxy. If they can't get money out of our miraculous molecule, Leronlimab, where will they profit? Hey, they will easily profit from there so called drugs that have so many side effects punishing people with them, that's where, UGH - GLTU Goose
HCIT/ahab333
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Shell Adjusts Q4 LNG Production Forecast Recently, Shell announced an adjustment to its liquefied natural gas (LNG) production outlook for the fourth quarter. The changes reflect updated expectations following market conditions and internal assessments. Revised LNG Production Estimates Shell now anticipates its LNG production for the quarter to fall within the range of...
Continue Reading
Major Transaction Announcement BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) recently shared exciting news, revealing their decision to sell the European segment of their ORLADEYO® (berotralstat) business to Neopharmed Gentili. This strategic move is valued at up to $264 million, comprising a notable upfront payment of $250 million. The deal aligns perfectly with...
Continue Reading
Community Engagement Takes Center Stage at SAS Championship Community initiative supports local teachers, sparks student interest in technology Teachers often face financial challenges covering classroom needs, especially in STEM (science, technology, engineering, and math) education, which is critical for preparing students for a tech-driven future. To alleviate this,...
Continue Reading
Lexar Unveils New PCIe 4.0 and PCIe 5.0 SSDs In a significant move for gamers and creative professionals, Lexar has introduced its latest line of SSDs aimed at elevating gameplay and enhancing professional applications. The new products come equipped with groundbreaking technology that accelerates performance and minimizes load times. Key Features of the NM1090 PRO PCIe...
Continue Reading
Get Ready for the World of Concrete Experience Sakrete, the leading bagged concrete materials brand, along with Amerimix, known for its pre-blended mortars and grouts, is preparing for an exciting showcase of their latest innovations at the World of Concrete event in Las Vegas. Visitors can anticipate a fully immersive experience at their booth, where the brands will...
Continue Reading